文献速递糖尿病

既往接受基础胰岛素治疗的2型糖尿病患者中每周一次基础胰岛素Fc的安全性与疗效:一项多中心、开放标签、随机、2期研究

Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study.
PubMed 文献 · Lancet Diabetes Endocrinol · 2023-02-06

这项在美国、波多黎各和墨西哥44个中心开展的2期、32周、随机、开放标签、对照研究,纳入既往使用基础胰岛素的2型糖尿病患者399例,随机分配至BIF-A1组、BIF-A2组或德谷胰岛素组。结果显示BIF组HbA1c较基线变化为-0.6%,德谷胰岛素组为-0.7%,BIF汇总分析相对德谷胰岛素达到非劣效;BIF组低血糖事件率较德谷胰岛素组低25%。

要点

  • 每周一次BIF(BIF-A1和BIF-A2)HbA1c较基线变化均为-0.6%,德谷胰岛素组为-0.7%。
  • BIF汇总分析相对德谷胰岛素HbA1c治疗差异为0.1%(90%CI -0.1至0.3),达到非劣效。
  • BIF-A1组低血糖事件率与德谷胰岛素组治疗比0.75(0.61-0.93),BIF-A2组为0.74(0.58-0.94)。

核心结论

  • 每周一次BIF尽管BIF组空腹血糖目标更高,仍达到与德谷胰岛素相似的疗效。
  • BIF组空腹血糖目标更高和血糖变异性更低可能促成BIF较德谷胰岛素更低的低血糖率。
  • 这些发现支持继续开发BIF作为糖尿病患者每周一次胰岛素治疗。

研究设计与样本

  • 2期、44个中心(临床研究中心和医院)、随机、开放标签、对照、32周研究,在美国、波多黎各和墨西哥开展。
  • 纳入年龄≥18岁、接受基础胰岛素和最多三种口服降糖药治疗的2型糖尿病患者。
  • 参与者按1:1:1随机分配至皮下注射BIF(BIF-A1组或BIF-A2组)或德谷胰岛素,随机按国家、基线HbA1c(<8.5%或≥8.5%;<69.4或≥69.4 mmol/mol)、磺脲类药物使用(是或否)和基线BMI(<30或≥30 kg/m2)分层。
  • BIF-A1组空腹血糖目标≤7.8 mmol/L(≤140 mg/dL)、每2周滴定;BIF-A2组≤6.7 mmol/L(≤120 mg/dL)、每4周滴定;德谷胰岛素组≤5.6 mmol/L(≤100 mg/dL)。
  • BIF组接受一次性负荷剂量为计算周剂量的1.5-3倍,首次周剂量在负荷剂量后1周给药;使用Dexcom G6连续血糖监测系统的间质空腹血糖测量滴定基础胰岛素。

主要发现

  • 2018年11月15日至2020年2月18日期间入组399例参与者,随机分配至BIF-A1组(n=135)、BIF-A2组(n=132)或德谷胰岛素组(n=132);202例(51%)为女性,197例(49%)为男性。
  • 379例纳入主要结局分析(BIF-A1组:n=130;BIF-A2组:n=125;德谷胰岛素组:n=124)。
  • 主要结局HbA1c从基线至第32周的平均变化:BIF-A1组为-0.6%(SE 0.1%),BIF-A2组为-0.6%(SE 0.1%),德谷胰岛素组为-0.7%(SE 0.1%)。
  • BIF汇总分析相对德谷胰岛素HbA1c治疗差异为0.1%(90%CI -0.1至0.3),达到非劣效(非劣效界值0.40%)。
  • 低血糖(≤3.9 mmol/L或≤70 mg/dL)事件率(每患者每年低血糖事件数):BIF-A1组与德谷胰岛素组治疗比为0.75(0.61-0.93),BIF-A2组与德谷胰岛素组治疗比为0.74(0.58-0.94),BIF组较德谷胰岛素组低25%。

关键数值与推荐

  • 主要疗效指标为BIF组HbA1c从基线至第32周的变化。
  • BIF与德谷胰岛素比较的非劣效界值为0.40%。
  • BIF-A1组空腹血糖目标≤7.8 mmol/L(≤140 mg/dL),每2周滴定。
  • BIF-A2组空腹血糖目标≤6.7 mmol/L(≤120 mg/dL),每4周滴定。
  • 德谷胰岛素组空腹血糖目标≤5.6 mmol/L(≤100 mg/dL)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The burden of daily basal insulins often causes hesitancy and delays in the initiation of insulin therapy. Basal insulin Fc (BIF, insulin efsitora alfa), designed for once-weekly administration, is a fusion protein combining a novel single-chain insulin variant with a human immunoglobulin G (IgG) Fc domain. In this study, we explored the safety and efficacy of BIF in people with type 2 diabetes who had been previously treated with basal insulin. METHODS: For this phase 2, 44-site (clinical research centres and hospitals), randomised, open-label, comparator-controlled, 32-week study in the USA, Puerto Rico, and Mexico, we enrolled participants with type 2 diabetes. Eligible participants had to be adults (aged ≥18 years) and to have been treated with basal insulin and up to three oral antidiabetic medicines. Participants were randomly assigned (1:1:1) to subcutaneous administration of BIF (BIF treatment group 1 [BIF-A1] or 2 [BIF-A2]) or insulin degludec. Randomisation was stratified by country, baseline HbA1c values (<8·5% or ≥8·5%; <69·4 or ≥69·4 mmol/mol), use of sulfonylureas (yes or no), and baseline BMI (<30 or ≥30 kg/m2). The randomisation scheme was performed using an interactive web-response system, which ensured balance between treatment groups. Different fasting glucose targets for the BIF-A1 (≤7·8 mmol/L or ≤140 mg/dL; titrated every 2 weeks), BIF-A2 (≤6·7 mmol/L or ≤120 mg/dL; titrated every 4 weeks), and degludec (≤5·6 mmol/L or ≤100 mg/dL) groups were selected. Patients randomly assigned to BIF received a one-time loading dose ranging from 1·5-3 times their calculated weekly dose. The first weekly dose was administered 1 week after the loading dose. We used interstitial fasting glucose measurements from the Dexcom G6 continuous glucose monitoring system to titrate the basal insulin. The primary measure of glycaemic control was change in HbA1c from baseline to week 32 for BIF. BIF was also compared with degludec (with a non-inferiority margin of 0·40%). The efficacy analysis set consisted of data from all randomised study participants who received at least one dose of the study medication and participants were analysed according to the treatment they were assigned. The safety population was the same as the efficacy analysis set. The completed trial is registered at ClinicalTrials.gov (NCT03736785). FINDINGS: Between Nov 15, 2018 and Feb 18, 2020, 399 participants were enrolled and randomised to BIF-A1 (n=135), BIF-A2 (n=132), or degludec (n=132); 202 (51%) were female and 197 (49%) were male. 379 were analysed for the primary outcome (BIF-A1: n=130; BIF-A2: n=125; degludec: n=124). Mean HbA1c change from baseline to week 32, the primary outcome, was -0·6% (SE 0·1%) for BIF-A1 and BIF-A2. Degludec achieved a change from baseline of -0·7% (0·1%). The pooled BIF analysis achieved non-inferiority versus degludec for the treatment difference in HbA1c (0·1% [90% CI -0·1 to 0·3]). The hypoglycaemia (≤3·9 mmol/L or ≤70 mg/dL) event rates (hypoglycaemia events per patient per year) in the BIF groups were 25% lower than those in the degludec group (treatment ratio BIF-A1 vs degludec was 0·75 [0·61-0·93]; and BIF-A2 vs degludec was 0·74 [0·58-0·94]). BIF was well tolerated; treatment-emergent adverse events were similar across groups. INTERPRETATION: Weekly BIF achieved a similar efficacy compared with degludec despite higher fasting glucose targets in the BIF groups. Higher fasting glucose targets and lower glucose variability might have contributed to lower hypoglycaemia rates for BIF compared with degludec. These findings support continued development of BIF as a once-weekly insulin treatment for people with diabetes. FUNDING: Eli Lilly and Company.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Frias J, Chien J, Zhang Q, et al. Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study. Lancet Diabetes Endocrinol. 2023. PMID: 36758572. doi:10.1016/S2213-8587(22)00388-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。